Maaziz N, Garrec C, Airaud F, Bobee V, Contentin N, Cayssials E
Genes (Basel). 2023; 14(5).
PMID: 37239426
PMC: 10217867.
DOI: 10.3390/genes14051066.
Li X, Liu J, Liu C
Front Oncol. 2022; 12:937362.
PMID: 36483035
PMC: 9723336.
DOI: 10.3389/fonc.2022.937362.
Regimbeau M, Mary R, Hermetet F, Girodon F
Genes (Basel). 2022; 13(4).
PMID: 35456443
PMC: 9027017.
DOI: 10.3390/genes13040637.
Langabeer S, Conneally E, Flynn C
Case Rep Hematol. 2018; 2018:4378310.
PMID: 29682367
PMC: 5842720.
DOI: 10.1155/2018/4378310.
Aral B, Courtois M, Ragot S, Bourgeois V, Bottolier-Lemallaz E, Briandet C
Haematologica. 2018; 103(8):e372-e373.
PMID: 29567786
PMC: 6068025.
DOI: 10.3324/haematol.2018.188995.
Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics.
Langabeer S
JAKSTAT. 2017; 5(2-4):e1248011.
PMID: 28144498
PMC: 5215010.
DOI: 10.1080/21623996.2016.1248011.
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.
Hermouet S, Bigot-Corbel E, Gardie B
Mediators Inflamm. 2015; 2015:145293.
PMID: 26538820
PMC: 4619950.
DOI: 10.1155/2015/145293.
The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?.
Boissinot M, Vilaine M, Hermouet S
Cancers (Basel). 2014; 6(3):1631-69.
PMID: 25119536
PMC: 4190560.
DOI: 10.3390/cancers6031631.
Mpl traffics to the cell surface through conventional and unconventional routes.
Cleyrat C, Darehshouri A, Steinkamp M, Vilaine M, Boassa D, Ellisman M
Traffic. 2014; 15(9):961-82.
PMID: 24931576
PMC: 4141020.
DOI: 10.1111/tra.12185.
Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
Li B, Zhang G, Li C, He D, Li X, Zhang C
PLoS One. 2012; 7(4):e34912.
PMID: 22523564
PMC: 3327703.
DOI: 10.1371/journal.pone.0034912.
The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?.
Hermouet S, Vilaine M
Haematologica. 2011; 96(11):1575-9.
PMID: 22058280
PMC: 3208673.
DOI: 10.3324/haematol.2011.055392.
Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations.
Lasho T, Tefferi A, Finke C, Pardanani A
Leukemia. 2011; 25(6):1056-8.
PMID: 21415853
DOI: 10.1038/leu.2011.45.
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.
Pietra D, Brisci A, Rumi E, Boggi S, Elena C, Pietrelli A
Haematologica. 2011; 96(4):607-11.
PMID: 21228032
PMC: 3069239.
DOI: 10.3324/haematol.2010.034793.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia. 2010; 24(6):1128-38.
PMID: 20428194
PMC: 3035972.
DOI: 10.1038/leu.2010.69.
